MarketBeat
25 Oct 2026, 10:03 UTC · 1h ago
Adagene Eyes Phase II Data for Masked CTLA-4 Therapy in MSS Colorectal Cancer
Impact · against what's priced in
The news is neutral to slightly positive for Adagene and Incyte, as it primarily provides a calendar for upcoming data readouts and reiterates known clinical benchmarks. The stock prices already reflect the current Phase Ib response rates and the company's liquidity position.
- ADAG+0.20
No priced-in read yet
- In context
Adagene provides a concrete timeline for Phase II data in MSS colorectal cancer (H1 2025) and neoadjuvant data (2027), while confirming a cash runway into H2 2028.
Read from the article alone
